Cocrystal Pharma (NASDAQ:COCP) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Cocrystal Pharma (NASDAQ:COCP) released its quarterly earnings results on Friday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports.

Cocrystal Pharma Trading Down 4.8%

COCP traded down $0.06 during mid-day trading on Friday, hitting $1.20. 101,244 shares of the stock were exchanged, compared to its average volume of 150,678. The firm’s fifty day moving average is $1.27 and its two-hundred day moving average is $1.11. Cocrystal Pharma has a 1-year low of $0.86 and a 1-year high of $2.67. The company has a market cap of $16.55 million, a PE ratio of -1.52 and a beta of 1.50.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.